Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomePreferred Dividend PaymentsProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Neuraxis (NRXS) EBT (2022 - 2025)

Historic EBT for Neuraxis (NRXS) over the last 4 years, with Q3 2025 value amounting to -$2.1 million.

  • Neuraxis' EBT fell 2411.48% to -$2.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$7.0 million, marking a year-over-year increase of 1202.8%. This contributed to the annual value of -$7.2 million for FY2024, which is 25.41% down from last year.
  • Latest data reveals that Neuraxis reported EBT of -$2.1 million as of Q3 2025, which was down 2411.48% from -$1.7 million recorded in Q2 2025.
  • In the past 5 years, Neuraxis' EBT registered a high of -$704032.0 during Q2 2022, and its lowest value of -$3.1 million during Q3 2023.
  • For the 4-year period, Neuraxis' EBT averaged around -$1.7 million, with its median value being -$1.7 million (2023).
  • Per our database at Business Quant, Neuraxis' EBT crashed by 13950.82% in 2023 and then surged by 4634.64% in 2024.
  • Over the past 4 years, Neuraxis' EBT (Quarter) stood at -$1.1 million in 2022, then plummeted by 43.91% to -$1.6 million in 2023, then skyrocketed by 46.35% to -$883005.0 in 2024, then plummeted by 141.19% to -$2.1 million in 2025.
  • Its EBT was -$2.1 million in Q3 2025, compared to -$1.7 million in Q2 2025 and -$2.3 million in Q1 2025.